First National Bank of Omaha Invests $12.55 Million in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• First National Bank of Omaha acquired 140,635 Zimmer Biomet shares worth approximately $12.55 million during the second quarter, giving it a 0.07% stake. Institutional investors collectively own 88.89% of the company.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 EPS versus the $2.01 consensus and $2.18 billion in revenue, up 4.8% year over year. The company maintained fiscal 2026 EPS guidance of $8.47–$8.59.
• The stock was trading at $99.31, while analysts maintained an overall “Hold” rating with an average price target of $104.42. Zimmer Biomet also pays a quarterly dividend of $0.24, equivalent to a 1.0% annualized yield.

First National Bank of Omaha acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 140,635 shares of the medical equipment provider's stock, valued at approximately $12,552,000. First National Bank of Omaha owned approximately 0.07% of Zimmer Biomet at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth $204,000. Sivia Capital Partners LLC purchased a new position in Zimmer Biomet in the second quarter valued at about $232,000. United Bank lifted its position in shares of Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock valued at $1,085,000 after acquiring an additional 1,153 shares during the period. Federated Hermes Inc. grew its holdings in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock worth $194,000 after acquiring an additional 1,202 shares during the period. Finally, Cerity Partners LLC raised its holdings in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock worth $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 1.1%

NYSE ZBH opened at $99.31 on Wednesday. The company's 50 day moving average price is $91.91 and its 200 day moving average price is $90.74. The firm has a market capitalization of $18.94 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 3.20 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the firm earned $2.07 earnings per share. The company's revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet's payout ratio is presently 23.36%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZBH. Wells Fargo & Company cut their price target on Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 29th. Citigroup cut their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a research report on Thursday, May 28th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Sanford C. Bernstein raised their price objective on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, Zimmer Biomet has an average rating of "Hold" and an average price target of $104.42.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source